ArticleScientific reports2026
Resveratrol alleviates neuropathic pain associated with restoration of mitochondrial fission-fusion balance in CCI mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neuropathic pain (NP) is commonly associated with mitochondrial dysfunction in sensory neurons. Although resveratrol (Res), a natural polyphenolic compound, has demonstrated analgesic properties, its impact on mitochondrial dynamics in NP remains unclear. We established a chronic constriction injury (CCI) model in male mice. Starting on the seventh day after the injury, resveratrol (1 mg/kg) or vehicle was administered via intrathecal injection for three consecutive days. We evaluated pain behaviors and analyzed dorsal root ganglia (DRG) for markers of oxidative stress, mitochondrial respiratory chain complexes, fission (DRP1) and fusion (OPA1) proteins, and mitochondrial morphology/ultrastructure. Resveratrol significantly reduced CCI-induced mechanical hypersensitivity and restored thermal latency. In DRG, reactive oxygen species (ROS) accumulation decreased, while superoxide dismutase (SOD) activity increased, indicating reduced oxidative stress. Mitochondrial respiratory chain complexes I–II were restored, while DRP1 expression decreased and OPA1 increased, suggesting a normalization of fission–fusion balance. Resveratrol also increased mitochondrial volume and number. Ultrastructural deficits in mitochondrial area, perimeter, and connectivity were reversed. Resveratrol mitigates CCI-induced NP associated with restoring the balance of mitochondrial fission and fusion proteins and reducing oxidative stress in DRG. These results provide credence to the idea of mitochondrial dynamics as a potential NP target. However, this study did not establish a causal relationship between these molecular changes and resveratrol’s analgesic effects through direct manipulation of proteins. Further validation is needed through experiments targeting key proteins involved in mitochondrial fission and fusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.